Treatment of heart failure with β-receptor-blockers;Therapie der herzinsuffizienz mit β-rezeptorenblockern

Deutsche Medizinische Wochenschrift

Volumn 127, Issue 13, 2002, Pages 682-688

  Schwinger, Robert H G ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; METOPROLOL; NEBIVOLOL;

BETA ADRENERGIC RECEPTOR BLOCKING; DRUG EFFICACY; HEART FAILURE; HUMAN; NORADRENALIN BLOOD LEVEL; REVIEW; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CHRONIC DISEASE; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; SURVIVAL RATE;

EID: 0037192568     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-23483     Document Type: Review

References (56)

1. β-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse
2. Effects of Carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease
3. Randomised, placebo-controlled trial of Carvedilol in patients with congestive heart failure due to ischemic heart disease
4. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure
5. Increase of Giα in human hearts with dilated but not ischemic cardiomyopathy
6. Effects of xamoterol on inotropic and lusitropic properties of the human myocardium and on adenylate cyclase activity
7. β-adrenergic receptor blockade in chronic heart failure
8. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
9. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy
10. Changes in myocardial and vascular receptors in heart failure
11. Mechanism of action of beta-blocking agents in heart failure
12. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium
13. 1-adrenoceptors in human myocardium
14. β-blockers, angiotensin II, and ACE inhibitors in patients with heart failure
15. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
16. A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS)
17. A randomized trial of the angiotensin-receptor-blocker valsartan in chronic heart failure
18. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
19. Effect of Carvedilol in severe chronic heart failure
20. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
21. 2-adrenergic receptors on cardiac myocyte apoptosis. Role of a pertussis toxin-sensitive G protein
22. αq overexpression induces cardiac contractile failure in mice
23. Progressive hypertrophy and heart failure in β1adrenergic receptor transgenic mice
24. Results from post-hoc analyses of the CIBIS II trial: Effect of bisoprolol in high-risk patient groups with chronic heart failure
25. Functional β3-adrenoceptor in the human heart
26. Overexpression of Gsα accelerates programmed death (apoptosis) of myocardiocytes in transgenic mice
27. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy
28. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart
29. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade
30. Leitlinien zur therapie der chronischen herzinsuffizienz
31. αs overexpression
32. Modulation of human cardiac function through 4 beta-adrenergic populations
33. Patients with end-stage congestive heart failure treated with β-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance
34. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency
35. The effect of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure
36. Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium
37. Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
38. Xamoterol in severe heart failure
39. Effect of carvedilol on survival in severe chronic heart failure
40. Double-blind, placebo-controlled study of the effects of Carvedilol in patients with moderate to severe heart failure: The PRECISE trial
41. Human beta 1- and beta 2-adrenergic receptor binding and mediated accumulation of cAMP in transfected Chinese hamster ovary cells. Profile of Nebivolol and known beta-adrenergic blockers
42. b1-adrenergic receptor
43. Different β-adrenoceptor-effector coupling in human ventricular and atrial myocardium
44. Effect of inotropic stimulation on the negative force-frequency-relationship in the failing human heart
45. Evidence against spare or uncoupled β-adrenoceptors in the human heart
46. Inotropic and lusitropic dysfunction in myocardium from patients with dilated cardiomyopathy
47. 2+-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation
48. The effect of xamoterol in failing human myocardium
49. Therapie der chronischen herzinsuffizienz mit β-rezeptorenblockern?
50. Therapie der herzinsuffizienz - State of the art
51. Hemodynamic predctors of early intolerance and long-term effects of propanolol in dilated cardiomyopathy
52. Expression of β-arrestins an β-adrenergic receptor kinases in the failing human heart
53. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist
54. A long-term beta-blockade in dilated cardiomyopathy. Effekts of short- and long-term metoprolol treatment followed by withdrawal and readmisnitration of metoprolol
55. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
56. Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathie